Drug news
Amgen files Procoralan for Heart Failure at FDA
Amgen announced in their second quarter 2014 financial earnings that they have submitted an NDA for Procoralan (ivabradine) for the treatment of Chronic Heart Failure in the US. Amgen licensed the product from Servier which markets the drug outside the US for Stable Angina and Heart Failure. The FDA has granted Fast Track status.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.